PDL BioPharma Financial Indicators Patterns

PDLI -- USA Stock  

USD 2.56  0.03  1.16%

We recommend you to use analysis of PDL BioPharma fundamentals to see if markets are today mispricing the firm. We found thirty-seven available financial ratios for PDL BioPharma which can be compared to its competitors. To make sure the equity is not overpriced, please check all PDL BioPharma fundamentals including its Price to Book, Total Debt, Number of Employees, as well as the relationship between EBITDA and Cash Flow from Operations . Please also confirm PDL BioPharma Price to Earning to check out the company can sustain itself for few more years.Use PDL BioPharma to protect against small markets fluctuations. The stock experiences somewhat bearish sentiment, but market may correct it shortly. Check odds of PDL BioPharma to be traded at $2.48 in 30 days

Enterprise Value

PDL BioPharma Company Summary

PDL BioPharma competes with China Cord, NantKwest, DelMar Pharmaceuticals, Denali Therapeutics, and DOVA. PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma operates under Biotechnology classification in USA and traded on NASDAQ. It employs 87 people.

PDL BioPharma Current Valuation vs Price to Book

PDL BioPharma is rated below average in current valuation category among related companies. It is rated below average in price to book category among related companies . The ratio of Current Valuation to Price to Book for PDL BioPharma is about  180,782,609 

PDL BioPharma Systematic Risk

The output start index for this execution was fourteen with a total number of output elements of three. The Beta measures systematic risk based on how returns on PDL BioPharma correlated with the market. If Beta is less than 0 PDL BioPharma generally moves in the opposite direction as compared to the market. If PDL BioPharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PDL BioPharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PDL BioPharma is generally in the same direction as the market. If Beta > 1 PDL BioPharma moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

Distress Rating

PDL BioPharma Financial Distress Probability
37% 
Chance of Financial Distress
PDL BioPharma has less than 37 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info
PDL BioPharma is an interesting company.? They really do not make anything.? Instead, the finance patents within the pharma industry, providing financial monetization ... continue

Active Themes That Utilize PDL BioPharma

This Stock does not participate in any thematic ideas. You can create a thematic portfolio hereView All Thematic Ideas

July 17, 2018 Opportunity Range

Additionally take a look at Your Equity Center. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.